Novartis Beats Patent Listing Suit Over Entresto

Дата публикации: 24-09-2026 20:13:13

A New York federal judge gave Novartis permanent relief from a proposed class action alleging it monopolistically delayed generic competition for its blockbuster heart failure drug Entresto, concluding that the drugmaker properly used a patent to ensure exclusivity.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Vein Tech Maker Escapes Suit Over DOJ Kickback Probe	0	9.63	23-09-2026
2	TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigation	0	8.67	27-04-2026
3	Oura Can't Force Ex-CEO's Stock Option Suit To Arbitration	0	9.34	25-09-2026
4	Waffle House Tobacco Fee Suit Stayed For Arbitration Bid	0	5.15	25-09-2026
5	Mortgage Co. Escapes Ex-Workers' 401(k) Forfeiture Suit	0	9.2	24-09-2026
6	Full 5th Circ. Tough On Aetna's Bid To Arbitrate Aramark Suit	0	7.94	24-09-2026
7	United, TeamHealth Settle $100M ER Billing Fraud Suit	0	9.23	25-09-2026
8	United States: Third Circuit Revives Algorithmic Pricing Case	0	10	03-08-2026
9	United States: DOJ Renews Expedited Merger Review	0	10	29-07-2026
10	TESARO, a GSK subsidiary, initiates litigation against AnaptysBio, Inc.	0	5.62	20-11-2025

Классификация: Экономика. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7.9. Источник: www.law360.com.